News

One of the most unique aspects of the Association for Research in Vision and Ophthalmology (ARVO) meeting that ophthalmic clinicians won't find at any other meeting-including the American Academy of Ophthalmology (AAO) and American Society of Refractive and Cataract Surgery (ASCRS) meetings-is the poster sessions.

Pseudoexfoliation syndrome (PEX) appears to be significantly associated with both cardiovascular (CVD) and cerebrovascular disease (CVA), according to a new meta-analysis, said Helen Chung, MD.

The cost of caring for patients with glaucoma has risen in the past decade, but at a lower rate than that of general or medical inflation. For Medicare beneficiaries, the greatest expense was not the treatment for glaucoma per se, but rather for cataracts and retinal eye care, said Harry Quigley, MD.

As of Tuesday afternoon at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting, all of the head-to-head comparison studies involving the efficacy and the safety of ranibizumab (Lucentis) and bevacizumab (Avastin) are officially IN.

A novel investigational agent appears to help control uncomfortable symptoms of dry eye. The results of OPUS-I, a phase III randomized clinical trial, found that lifitegrast demonstrated superiority to placebo in reducing corneal fluorescein and conjunctival lissamine staining.

Ranibizumab and bevacizumab appear to be equally effective for the treatment age-related macular degeneration (AMD). The results of two large randomized multicenter trials-the IVAN and GEFAL-found that both drugs had similar effects on vision acuity and lesion morphology.

Adequate levels of vitamin D can decrease the risk of age-related macular degeneration (AMD), but most markedly in individuals with two risk alleles for the CFH Y402H genotype, said Amy Millen, PhD.

Primary open-angle glaucoma is generally associated with elevations in IOP, and damage to the cells residing within the trabecular meshwork is most likely a contributing factor, said Markus H. Kuehn, PhD.

Long-term results reveal that intravitreal ranibizumab (Lucentis, Genentech) has made a marked difference in the rates of blindness related to wet age-related macular degeneration (AMD), said Peter Cackett, MB BS.

The addition of the carotenoids, lutein and zeaxanthin, and the omega-3 fatty acids, DHA and EPA, to a supplement formulation does not further reduce the risk of disease progression in age-related macular degeneration (AMD), said Emily Y. Chew, MD.

The results of the long-awaited Age-Related Eye Disease Study 2 (AREDS2) were officially released Sunday afternoon during a special session at the Association for Research in Vision and Ophthalmology meeting in Seattle-and the study results really did not come as a surprise to most in the eye-care community.

Lens assessment with femtosecond laser imaging offers opportunity for cataract outcomes

Making a diagnosis is only the first step in treating dry eye syndrome

Pre-emptive strategies for exacerbations guided by seasonal fluctuations

Pre-existing dry eye should be identified and controlled before surgery is considered

Two cases illustrate benefits in managing dry eye before, after surgery with premium lens implantation

LASIK can be an option after management to normalize ocular surface

Challenging cases achieve good refractive outcomes with intraoperative aberrometry

Phase III study of RPE65 for Leber’s congenital amaurosis under way, among other research

SLO-MP shows higher structure/function correlation compared with standard perimetry

Management requires aggressive therapy of inflammation, medical therapy of elevated IOP

Phase III study of RPE65 for Leber’s congenital amaurosis under way, among other research

Man has 3-day history of OD pain, decreased vision, other symptoms: What is diagnosis?

Why unintended consequences can have bad results

Why an effective campaign must be readily available for physicians to implement

Avoiding hypotropia, excyclotropia after augmented transposition surgery among tips

The journey to achieving the perfect lens calculation is now just a few years away from reaching its destination.

The FDA has approved Simbrinza suspension (Alcon) for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

A team of scientists reports that it has found a way to isolate retinal pigment epithelium cells from human pluripotent stem cells as early as 14 days following the onset of differentiation.

The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of cataract patients with pre-existing corneal astigmatism.